Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI.
Department of Surgery, Massachusetts General Hospital, Boston, MA.
Transplantation. 2021 Jan 1;105(1):100-107. doi: 10.1097/TP.0000000000003155.
Opioid use in liver transplantation is poorly understood and has potential associated morbidity.
Using a national data set of employer-based insurance claims, we identified 1257 adults who underwent liver transplantation between December 2009 and February 2015. We categorized patients based on their duration of opioid fills over the year before and after transplant admission as opioid-naive/no fills, chronic opioid use (≥120 d supply), and intermittent use (all other use). We calculated risk-adjusted prevalence of peritransplant opioid fills, assessed changes in opioid use after transplant, and identified correlates of persistent or increased opioid use posttransplant.
Overall, 45% of patients filled ≥1 opioid prescription in the year before transplant (35% intermittent use, 10% chronic). Posttransplant, 61% of patients filled an opioid prescription 0-2 months after discharge, and 21% filled an opioid between 10-12 months after discharge. Among previously opioid-naive patients, 4% developed chronic use posttransplant. Among patients with pretransplant opioid use, 84% remained intermittent or increased to chronic use, and 73% of chronic users remained chronic users after transplant. Pretransplant opioid use (risk factor) and hepatobiliary malignancy (protective) were the only factors independently associated with risk of persistent or increased posttransplant opioid use.
Prescription opioid use is common before and after liver transplant, with intermittent and chronic use largely persisting, and a small development of new chronic use posttransplant. To minimize the morbidity of long-term opioid use, it is critical to improve pain management and optimize opioid use before and after liver transplant.
肝移植患者中阿片类药物的使用情况了解甚少,且可能会引起相关发病率。
利用全国雇主医疗保险理赔数据库,我们确定了 1257 名在 2009 年 12 月至 2015 年 2 月期间接受肝移植的成年人。我们根据患者在肝移植入院前和入院后一年中阿片类药物的使用时间将其分类为阿片类药物初治/未使用(无阿片类药物使用)、慢性阿片类药物使用(≥120 天供应量)和间歇性使用(其他所有使用)。我们计算了肝移植前和肝移植后围手术期阿片类药物使用的风险调整后发生率,评估了肝移植后阿片类药物使用的变化,并确定了肝移植后持续或增加阿片类药物使用的相关因素。
总体而言,45%的患者在肝移植前一年中至少有一次阿片类药物处方(35%为间歇性使用,10%为慢性使用)。肝移植后,61%的患者在出院后 0-2 个月内开具了阿片类药物处方,21%的患者在出院后 10-12 个月内开具了阿片类药物处方。在之前未使用过阿片类药物的患者中,有 4%的患者在肝移植后出现慢性使用。在有肝移植前阿片类药物使用史的患者中,84%的患者继续间歇性使用或增加为慢性使用,73%的慢性使用者在肝移植后仍为慢性使用者。肝移植前的阿片类药物使用(风险因素)和肝胆恶性肿瘤(保护因素)是唯一与肝移植后持续或增加阿片类药物使用风险相关的因素。
肝移植前后开阿片类药物处方很常见,间歇性和慢性使用基本持续,并且术后新出现慢性使用的情况很少。为了最大限度地降低长期使用阿片类药物的发病率,在肝移植前后改善疼痛管理和优化阿片类药物使用至关重要。